Table 1 Preintervention and postintervention study characteristics
From: Streamlining and cycle time reduction of the startup phase of clinical trials
Study characteristics | Preintervention (n = 8) n (%) | Postintervention (n = 5) n (%) |
|---|---|---|
Health field | ||
Cardiac and pulmonary | 5 (62.5) | 3 (60.0) |
Cancer and hematology | 3 (37.5) | 2 (40.0) |
Patient population | ||
Adult | 6 (75.0) | 4 (80.0) |
Pediatric | 2 (25.0) | 1 (20.0) |
Industry-sponsored study | 8 (100) | 5 (100) |
Study intervention | ||
Drug | 8 (100) | 5 (100) |
Phase | ||
III | 5 (62.5) | 3 (60.0) |
IV | 3 (37.5) | 2 (40.0) |
International studies/multicenter studies | 8 (100) | 5 (100) |